title: Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
abstract: BACKGROUND
  The nuclear enzyme topoisomerase IIα (TopoIIα) is able to cleave DNA in a reversible manner, making it a valuable target for agents such as etoposide that trap the enzyme in a covalent bond with the 5' DNA end to which it cleaves. This prevents DNA religation and triggers cell death in cancer cells. However, development of resistance to these agents limits their therapeutic use. In this study, we examined the therapeutic targeting of geminin for improving the therapeutic potential of TopoIIα agents.
  
  
  METHODS
  Human mammary epithelial (HME) cells and several breast cancer cell lines were used in this study. Geminin, TopoIIα and cell division cycle 7 (Cdc7) silencing were done using specific small interfering RNA. Transit or stable inducible overexpression of these proteins and casein kinase Iε (CKIε) were also used, as well as several pharmacological inhibitors that target TopoIIα, Cdc7 or CKIε. We manipulated HME cells that expressed H2B-GFP, or did not, to detect chromosome bridges. Immunoprecipitation and direct Western blot analysis were used to detect interactions between these proteins and their total expression, respectively, whereas interactions on chromosomal arms were detected using a trapped in agarose DNA immunostaining assay. TopoIIα phosphorylation by Cdc7 or CKIε was done using an in vitro kinase assay. The TopoGen decatenation kit was used to measure TopoIIα decatenation activity. Finally, a comet assay and metaphase chromosome spread were used to detect chromosome breakage and changes in chromosome condensation or numbers, respectively.
  
  
  RESULTS
  We found that geminin and TopoIIα interact primarily in G2/M/early G1 cells on chromosomes, that geminin recruits TopoIIα to chromosomal decatenation sites or vice versa and that geminin silencing in HME cells triggers the formation of chromosome bridges by suppressing TopoIIα access to chromosomal arms. CKIε kinase phosphorylates and positively regulates TopoIIα chromosome localization and function. CKIε kinase overexpression or Cdc7 kinase silencing, which we show phosphorylates TopoIIα in vitro, restored DNA decatenation and chromosome segregation in geminin-silenced cells before triggering cell death. In vivo, at normal concentration, geminin recruits the deSUMOylating sentrin-specific proteases SENP1 and SENP2 enzymes to deSUMOylate chromosome-bound TopoIIα and promote its release from chromosomes following completion of DNA decatenation. In cells overexpressing geminin, premature departure of TopoIIα from chromosomes is thought to be due to the fact that geminin recruits more of these deSUMOylating enzymes, or recruits them earlier, to bound TopoIIα. This triggers premature release of TopoIIα from chromosomes, which we propose induces aneuploidy in HME cells, since chromosome breakage generated through this mechanism were not sensed and/or repaired and the cell cycle was not arrested. Expression of mitosis-inducing proteins such as cyclin A and cell division kinase 1 was also increased in these cells because of the overexpression of geminin.
  
  
  CONCLUSIONS
  TopoIIα recruitment and its chromosome decatenation function require a normal level of geminin. Geminin silencing induces a cytokinetic checkpoint in which Cdc7 phosphorylates TopoIIα and inhibits its chromosomal recruitment and decatenation and/or segregation function. Geminin overexpression prematurely deSUMOylates TopoIIα, triggering its premature departure from chromosomes and leading to chromosomal abnormalities and the formation of aneuploid, drug-resistant cancer cells. On the basis of our findings, we propose that therapeutic targeting of geminin is essential for improving the therapeutic potential of TopoIIα agents.
authors: Cancer Institute, Department of Biochemistry, University of Mississippi Medical Center, Jackson, 39216, USA.
authors: Lauren
authors: L
authors: Gardner
authors: Rohit
authors: R
authors: Malik
authors: Yoshiko
authors: Y
authors: Shimizu
authors: Nicole
authors: N
authors: Mullins
authors: Wael M
authors: WM
authors: ElShamy
references: Genes Dev. 1997 Oct 1;11(19):2580-92
references: 9334322
references: Nat Cell Biol. 2001 Feb;3(2):E49-50
references: 11175762
references: Mutat Res. 2005 Apr 4;582(1-2):79-86
references: 15781213
references: Prog Nucleic Acid Res Mol Biol. 1986;33:111-40
references: 3541040
references: Br J Cancer. 1993 Mar;67(3):456-63
references: 8382508
references: Cancer Res. 2009 Jun 1;69(11):4870-7
references: 19487297
references: Curr Opin Cell Biol. 1994 Feb;6(1):41-9
references: 8167024
references: Cell. 2008 Apr 4;133(1):103-15
references: 18394993
references: Mutat Res. 2003 Nov 27;532(1-2):29-40
references: 14643427
references: Biochem Pharmacol. 1997 Oct 1;54(7):755-9
references: 9353129
references: Nat Cell Biol. 2004 Oct;6(10):954-67
references: 15448696
references: J Cell Biochem. 2008 Jun 1;104(3):1075-86
references: 18286467
references: J Biol Chem. 1994 Oct 7;269(40):24523-6
references: 7929118
references: EMBO J. 2001 Nov 15;20(22):6509-19
references: 11707421
references: J Mol Biol. 2004 Sep 3;342(1):275-87
references: 15313623
references: Mol Pharmacol. 1998 Jul;54(1):78-85
references: 9658192
references: J Med Chem. 2009 Jan 22;52(2):293-307
references: 19115845
references: Biol Cell. 2009 May;101(5):273-85
references: 18798731
references: Nature. 2000 Jun 8;405(6787):697-700
references: 10864328
references: Biochem J. 1994 Nov 1;303 ( Pt 3):681-95
references: 7980433
references: DNA Repair (Amst). 2006 Sep 8;5(9-10):1093-108
references: 16857431
references: Adv Pharmacol. 1994;29B:105-26
references: 8996604
references: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18832-7
references: 20921377
references: J Biol Chem. 1989 Sep 15;264(26):15161-4
references: 2549053
references: Genes Dev. 2001 Oct 15;15(20):2741-54
references: 11641279
references: Mutat Res. 2005 Jan 6;569(1-2):111-21
references: 15603756
references: Mol Cell. 2004 Sep 24;15(6):977-90
references: 15383286
references: Mol Biol Cell. 2006 Oct;17(10):4459-72
references: 16899510
references: Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40
references: 12042765
references: Science. 2000 Dec 22;290(5500):2309-12
references: 11125146
references: Biochem J. 2010 Sep 1;430(2):335-44
references: 20590526
references: Cell Cycle. 2003 Jul-Aug;2(4):283-6
references: 12851473
references: EMBO J. 2005 Jan 26;24(2):395-404
references: 15616577
references: Cell. 1998 Jun 12;93(6):1043-53
references: 9635433
references: Nat Cell Biol. 2001 Feb;3(2):107-13
references: 11175741
references: Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):8988-93
references: 9256422
references: Cytogenet Genome Res. 2007;116(1-2):38-45
references: 17268176
references: Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8895-9
references: 1656458
references: J Biol Chem. 2010 Aug 13;285(33):25699-707
references: 20516064
references: EMBO Rep. 2004 Mar;5(3):256-61
references: 14993926
references: Genes Dev. 2000 Nov 15;14(22):2881-92
references: 11090135
references: Eur J Cell Biol. 2002 Jan;81(1):9-16
references: 11893079
references: Nat Cell Biol. 2009 Jun;11(6):753-60
references: 19465922
references: Development. 2004 Oct;131(19):4807-18
references: 15342466
references: Nucleic Acids Res. 2009 Feb;37(2):382-92
references: 19043076
references: Cell. 1998 Sep 18;94(6):819-27
references: 9753328
references: Genetica. 1999;106(1-2):131-40
references: 10710719
references: J Cell Sci. 2000 Jun;113 ( Pt 12):2111-7
references: 10825284
references: Genes Cells. 2006 Nov;11(11):1281-93
references: 17054725
references: Environ Mol Mutagen. 2008 Jan;49(1):73-82
references: 18095327
references: J Biol Chem. 2008 Sep 12;283(37):25171-25177
references: 18625709
references: Oncogene. 2002 Oct 7;21(45):6884-97
references: 12362271
references: Eur J Biochem. 2003 Oct;270(19):3859-70
references: 14511368
references: J Biol Chem. 2005 Apr 1;280(13):13062-70
references: 15668232
references: J Biol Chem. 1987 Jul 25;262(21):10327-34
references: 3038874
references: Nature. 1995 Feb 16;373(6515):630-2
references: 7854422
references: J Clin Oncol. 2006 Apr 10;24(11):1770-83
references: 16603719
references: J Biol Chem. 2004 Jul 16;279(29):30807-16
references: 15138268
references: Cell. 1996 Dec 13;87(6):1103-14
references: 8978614
references: J Cell Physiol. 2002 Mar;190(3):287-96
references: 11857444
references: Genes Dev. 2005 Jan 1;19(1):114-26
references: 15598982
references: Int J Biochem Cell Biol. 2006;38(7):1207-20
references: 16487741
references: J Biol Chem. 2003 Dec 5;278(49):48779-85
references: 14512422
references: J Biol Chem. 2006 Dec 22;281(51):39249-61
references: 17046832
references: J Biol Chem. 1994 Nov 25;269(47):29746-51
references: 7961967
references: Genes Cells. 2005 Jan;10(1):63-73
references: 15670214
references: Cancer Res. 1993 Jul 1;53(13):3186-92
references: 8319228
references: Cell Cycle. 2004 Aug;3(8):1002-4
references: 15280663
references: EMBO J. 2006 Dec 13;25(24):5764-74
references: 17124498
references: J Biol Chem. 2002 Oct 25;277(43):40871-80
references: 12192004
references: Curr Biol. 2005 Jan 26;15(2):146-53
references: 15668171
references: J Biol Chem. 2009 Oct 16;284(42):28823-31
references: 19692334
references: Cancer Res. 1992 Aug 15;52(16):4467-72
references: 1322791
references: Science. 2000 Dec 22;290(5500):2271-3
references: 11188727
references: Oncogene. 2008 May 29;27(24):3475-82
references: 18084324
references: Cancer Res. 2003 Jul 15;63(14):4074-81
references: 12874009
references: J Biol Chem. 2003 Apr 11;278(15):12696-702
references: 12569090
references: Cancer Res. 2004 Oct 1;64(19):7110-6
references: 15466207